ADMA Biologics (NASDAQ:ADMA), Inc. is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S. Food and Drug Administration (FDA) in 2012 for patients with primary humoral immunodeficiency, and ASCENIV, a high-titer IGIV approved in 2019 for the treatment of similar conditions with targeted antibody coverage against pathogens such as respiratory syncytial virus (RSV). Both products are manufactured in ADMA’s FDA-licensed biologics facility in Boca Raton, Florida, and distributed across the United States through a network of specialty pharmacy and hospital partners.
Founded in 2008 and completing its initial public offering in 2011, ADMA Biologics has invested in expanding its plasma supply chain and production capacity to support long-term growth. The company sources plasma exclusively from U.S. donations, operating its own collection centers while also collaborating with third-party providers to ensure a consistent supply of raw materials for fractionation and downstream processing.
ADMA Biologics is led by President and Chief Executive Officer Adam Grossman, who brings experience in both commercial operations and regulatory affairs within the biopharmaceutical sector. Under his leadership, the company continues to explore new indications for immunoglobulin therapies and to advance its pipeline of additional plasma-derived products designed to enhance patient access and outcomes.
